First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Biotechnology

Healthcare
$44.50 -4.87%

-$0.89 today

Market cap
$1.87B
Beta
0.00
P/E (TTM)
-6.1
EPS (TTM)
-$2.81
52W Low $14.72High $26.80

Volume 0.75M

Average 0.43M

TRAX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

First Tracks Biotherapeutics IncNASDAQ: TRAX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$52.69M, compared with -$50.67M a year earlier.

Context

  • EBITDA grew in size in 1 of the last 2 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$52.69M— QoQ
Last fiscal yearDec 2025
-$178.45M+0.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.0%——
1 year+0.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

EBITDA history

USD · from the income statement

Latest · FY2025
(178.45M) USD
Year-over-year change
+0.1%

EBITDA vs competitors

How TRAX compares with its peers on the latest reported figures

  • TRAX's FY2025 EBITDA of -$178.45M is the 8th highest of the 10 companies compared; the peer median is -$70.61M.
  • Its year-over-year change of +0.1% is the 4th highest of 10, against a peer median of -10.4%.
TRAX Competitors Peer median
EBITDA for TRAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$58.49M +176.6%—25.2%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026-$9.46M +71.7%——
CLYMClimb Bio, Inc.LTM Mar 2026-$52.66M +43.4%——
ATTOAttovia Therapeutics, Inc.FY2025-$66.36M -60.9%—4915.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M -31.5%—843.9%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026-$78.03M -325.2%——
IMUXImmunic, Inc.LTM Mar 2026-$104.13M -8.2%——
TRAXFirst Tracks Biotherapeutics IncFY2025-$178.45M +0.1%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$245.81M -69.1%——
IMVTImmunovant, Inc.LTM Sep 2026-$509.88M -10.4%—7186.4%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding TRAX) -$70.61M-10.4%—2879.6%

Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue0152.35M139.61M
Gross Profit0(152.35M)(139.61M)
Gross Margin———
Research & Development97.59M152.35M139.61M
Selling, General & Admin20.87M28.76M39.39M
Operating Expenses118.46M28.76M39.39M
Depreciation & Amortization2.38M2.4M559K
EBITDA(116.09M)(178.7M)(178.45M)
EBITDA Margin———
Operating Income(118.46M)(181.1M)(179.01M)
Operating Margin———
Interest Income12.31M17.38M0
Interest Expense000
Other Income / Expenses12.31M17.4M12.92M
Income Before Tax(106.15M)(163.71M)(166.09M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(106.15M)(163.71M)(166.09M)
Net Margin———
EPS (Basic)(3.05)0.000.00
EPS (Diluted)(3.05)0.000.00
Weighted Avg Shares34.75M00
Weighted Avg Shares (Diluted)34.75M00

First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Intrinsic Alpha fair value

Locked

Current Price

$44.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.